News

November 30, 2017 12:00 pm
ASH 2017: Actinium Labeled Daratumumab Shows Enhanced Killing of Myeloma Cells over Naked Daratumumab - A new therapeutic approach of “turbo-charging” daratumumab (Darzalex), the monoclonal antibody drug that targets the myeloma protein CD38, is...
November 29, 2017 12:00 pm
 Emerging Therapies for Multiple Myeloma Including Updates from the ASCO® 2017 Annual Meeting – LLS Program Audio Replay and Transcript Available, Presenter: Ajai Chari, MD,  Mount Sinai Hospital, Originally Presented June 22, 2017  
November 17, 2017 12:00 pm
Myeloma bb2121 CAR T Therapy Receives FDA Breakthrough Status - The FDA announced that the bb2121 CAR-T therapy now has FDA breakthrough status, meaning that it will get an accelerated view by the FDA through the approval process. This is based on...
November 16, 2017 12:00 pm
The LLS Myeloma Co-Pay Silo has reopened! - However, funding is very limited and it is  anticipated to becomefully subscribed quickly (approximately 1 -2 weeks). Patient demand for myeloma co-pay assistance remains high and currently, LLS is the...

Pages